Acadia Pharmaceuticals’ CEO on Rebranding and Using AI
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand and expansion into rare disease marketing, as well as its use of AI.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it seeks to expand into the rare disease space, with AI playing a major role in its marketing strategy.
MM+M spoke with Acadia CEO Catherine Owen Adams on the company's recent rebrand, its expansion into rare disease and how it's using AI throughout commercialization and marketing.
Adams also shares her insights on the benefits and challenges of marketing as a smaller biotech and how her marketing background is helping to steer the company into 2026.
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI.
More News
- Supreme Court Declines to Hear Corner-Crossing Case
- Who Killed the Montreal Expos? Review: Vive les Expos! - POV Magazine
- 75% of Amazon's Code Now AI-Generated? Musk Mocks After AWS Outage
- AWS DNS Failure Shuts Down Alexa, Fortnite, ChatGPT, PlayStation Network, and More
- Two Killed in Hong Kong Cargo Plane Crash
- Colman Domingo Is the Cowardly Lion in 'Wicked: For Good'
- Developers Share Funding To Create Innovative Video Games
- Son of ex-England football captain killed in tractor crash near Cirencester
- ICC dismisses Israel's appeal against arrest warrants for Netanyahu, Gallant
- A Secret Cameo and a Childhood Flashback - All the Changes Coming to Wicked: For Good